# AI and drug development: Axiom live on CNBC! 🎥 | Axiom Biosciences

- Canonical URL: https://wefunder.com/feed/378840
- Entity ID: wefunder:feed_item:378840
- Published at: 2026-09-04 15:07:53 UTC
- Updated at: 2026-09-04 15:07:53 UTC

## Author
Remo Moomiaie

## Subject
Axiom Biosciences

## Content
We recently announced our plan to pursue a primary listing on the Hong Kong Stock Exchange in 2027, with a Nasdaq listing to follow in 2029. It's a milestone years in the making, and the response since has been incredible.🎉Along with the announcement came a wave of press, including an interview with CNBC.Check out the interview hereNaturally, one of the questions was about AI and I want to share with you a bit more about how AI fits into our strategy of developing next generation genetic medicines.First, we start with delivery platforms, engineered systems like nanoparticles, and fusion proteins that get a therapy to the right place in the body at the right time. That's what sets our approach apart: we solve delivery before we ever touch molecule design.Once a delivery platform is established, we use AI to design the molecules it carries. AI has been an unbelievable opportunity for us, giving us a plug-and-play path through drug development, and hopefully through regulatory review too.🧬This AI-driven approach is already behind three programs: a fusion-protein therapy for atopic dermatitis, an in vivo CAR-T program for autoimmune disease, and a cancer vaccine, all still in preclinical development.We've raised $21M to date and hold 9 issued patents with 50 more pending, funding both engines at once.If you haven't invested yet, now's a good time to join us. If you already have, there's still room to increase your stake.Invest or increase your investment now →Here's to the science already working, and the AI helping build what's next.✨Remo Moomiaie-Qajar, MDFounder & CEO, Axiom Biosciences